support_agent

Your contact persons

CHEPLAPHARM Arzneimittel GmbH

View:
format_list_bulleted grid_view

03/25/2019

CHEPLAPHARM celebrates topping-out ceremony

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its headquarters in the Hanseatic town of Greifswald…


Archive
Read more chevron_right

11/23/2018

CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in mid-November.


Archive
Read more chevron_right

08/06/2018

CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and…


Archive
Read more chevron_right

06/19/2018

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.


Archive
Read more chevron_right

08/09/2017

Mysimba®: Commercialization and distributorship arrangement with Orexigen Therapeutics Ireland, Ltd.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba®…


Archive
Read more chevron_right

02/24/2017

50 new employees: CHEPLAPHARM’s successful story continues

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight months.


Archive
Read more chevron_right

10/27/2016

Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western Pomerania and moves into the big league for medium-sized…


Archive
Read more chevron_right

12/02/2015

CHEPLAPHARM assumes Italian rights for ALDACTONE®

CHEPLAPHARM acquired the product rights for the prescription medication ALDACTONE® in Italy on 09.11.2015, thus boosting its presence within this market that is very important to CHEPLAPHARM.


Archive
Read more chevron_right

12/01/2015

CHEPLAPHARM moves into new 2500 square meter office building at Greifswald’s Business Park Ziegelhof
Archive
Read more chevron_right

Back

Back to top expand_less